BioInvent International AB (OSTO:BINV) Other Current Liabilities : kr74.81 Mil (As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is BioInvent International AB Other Current Liabilities?

BioInvent International AB's other current liabilities for the quarter that ended in Mar. 2024 was kr74.81 Mil.

BioInvent International AB's quarterly other current liabilities declined from Sep. 2023 (kr55.58 Mil) to Dec. 2023 (kr38.02 Mil) but then increased from Dec. 2023 (kr38.02 Mil) to Mar. 2024 (kr74.81 Mil).

BioInvent International AB's annual other current liabilities increased from Dec. 2021 (kr32.24 Mil) to Dec. 2022 (kr37.78 Mil) and increased from Dec. 2022 (kr37.78 Mil) to Dec. 2023 (kr38.02 Mil).

BioInvent International AB Other Current Liabilities Historical Data

The historical data trend for BioInvent International AB's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioInvent International AB Other Current Liabilities Chart

BioInvent International AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Liabilities

Get a 7-Day Free Trial

BioInvent International AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Current Liabilities	Get a 7-Day Free Trial															-	-	-	-	-

BioInvent International AB Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

BioInvent International AB Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of BioInvent International AB's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

BioInvent International AB (OSTO:BINV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioInvent International AB (OSTO:BINV) » Definitions » Other Current Liabilities

Comparable Companies

Traded in Other Exchanges

0H22:UK BIX:Germany

Address

Ideongatan 1, The Gamma Building, Lund, SWE, SE-223 70

Website

https://www.bioinvent.com

BioInvent International AB is a clinical-stage biotech company. It discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently four drug candidates in five ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively. The company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many new drug candidates to fuel the company's own clinical development pipeline and providing licensing and partnering opportunities. The company's pipeline portfolio comprises BI-1206, an antagonistic blocking antibody for the treatment of non-Hodgkin's lymphoma, and BI-1808 and BI-1910 (anti-TNFR2) for solid cancers.

BioInvent International AB (OSTO:BINV) Headlines

No Headlines